Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Watches of Switzerland beats profit guidance with strong US sales driving record revenue.

Company Fundamentals
14 May 2026
Proactive Investors
View Source
Bullish
pluang ai news

Watches of Switzerland Group PLC reported a 13% revenue increase to £1.83 billion for the year ending May 3, driven by a 24% rise in US sales which now represent over half of total sales and profits. The company raised its profit guidance with adjusted EBIT expected between £152 million and £155 million, surpassing previous estimates. Growth was also seen in the UK market and across luxury watch, jewellery, pre-owned watch sales, and ecommerce channels. For 2027, the group forecasts 5-10% revenue growth and margin expansion, supported by new showroom projects and the acquisition of Deutsch & Deutsch. Despite geopolitical risks, the company has minimal exposure to the Middle East or tourist-dependent markets.

More News

Pension officials criticize SpaceX's IPO structure as overly favorable to Elon Musk's control.

Pension officials criticize SpaceX's IPO structure as overly favorable to Elon Musk's control.

Top pension officials from New York and California have expressed concerns about SpaceX's upcoming IPO, criticizing its dual-class share structure that grants Elon Musk significant voting power and control. They warn that this 'most management-favora...

Market News
Bearish
28 minutes ago
Ipsen presents corabotase, a novel neuro-inhibitor, showing promising phase II results for facial wrinkle treatment.

Ipsen presents corabotase, a novel neuro-inhibitor, showing promising phase II results for facial wrinkle treatment.

Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuro-inhibitors, at the SCALE symposium. Phase II trial data show corabotase's safety and efficacy in treating moderate to severe facial wrinkles, including glabellar ...

Market News
Bullish
1 hour ago
Ipsen unveils corabotase, a novel neuroinhibitor, showing promising Phase II results for facial line treatment.

Ipsen unveils corabotase, a novel neuroinhibitor, showing promising Phase II results for facial line treatment.

Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuroinhibitors, designed to treat moderate to severe upper facial lines such as glabellar lines. Phase II trial data presented at the SCALE Symposium showed corabotase...

Others
Bullish
1 hour ago
Forward Industries faces nearly $1B unrealized loss on Solana holdings but sees 4x revenue growth from staking.

Forward Industries faces nearly $1B unrealized loss on Solana holdings but sees 4x revenue growth from staking.

Forward Industries, the largest listed Solana treasury firm, holds nearly 7 million SOL tokens bought at $232 each, resulting in an unrealized loss close to $1 billion due to Solana's lower market price. Despite this, the company reported a 4x increa...

Protocol Fundamentals
Bearish
4 hours ago
NY judge delays decision on releasing $71M frozen ETH linked to Kelp DAO hack, requests more legal arguments.

NY judge delays decision on releasing $71M frozen ETH linked to Kelp DAO hack, requests more legal arguments.

A New York federal judge postponed ruling on Aave's request to release $71 million in frozen Ethereum tied to the Kelp DAO exploit, citing insufficient explanation on potential user losses. The court ordered both Aave and Gerstein Harrow LLP to submi...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App